1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends

Physician Views: What opportunity for Novo Nordisk’s Victoza in obesity?

  • November 2013
  • Firstword Pharma
Report ID: 1911244


Table of Contents


Analysts have notably mixed opinions on the commercial opportunity, but one of the more intriguing near-term catalysts for Novo Nordisk is potential FDA approval of Victoza (its GLP-1 anti-diabetic) for the treatment of obesity.

Most recent Phase III data – published in May – supports a consensus view that Victoza will be filed for obesity and stands a strong chance of gaining approval. Whether regulatory progress can translate into commercial success remains to be seen, however.

Versus placebo (in the 56-week SCALE study), Victoza demonstrated a statistically significant difference in obese non-diabetic patients, including average weight loss of 8 percent for Victoza compared to 2.6 percent for placebo. Furthermore, 64 percent of Victoza patients achieved greater than 5 percent weight loss and 33 percent achieved greater than 10 percent weight loss. Mean weight loss of 5.4 percent was above the 5 percent threshold required by the FDA.

However, perhaps the most significant data from SCALE pointed to Victoza's potential use in pre-diabetes patients. Of the 61 percent of patients with pre-diabetes at randomisation, 69 percent treated with Victoza no longer showed signs of diabetes compared to 33 percent for placebo (at 56 weeks). Furthermore, for patients without pre-diabetes at the start of the study, the chance of developing pre-diabetes was reduced from 21 percent with placebo to 7 percent with Victoza.

Analysts have suggested that this data could potentially differentiate Victoza in the obesity setting, assuming approval is secured. Possibly offsetting this benefit is the likely more expensive cost of Novo Nordisk's product and its administration via injection (versus the cheaper cost and oral availability of competing obesity treatments).

Commercial expectations for Victoza in obesity were dealt something of a blow when the drug failed to demonstrate compelling data in obese diabetes patients. Nevertheless, analyst models currently reflect a broad perception of uptake for obesity in non-diabetic patients, ranging from no revenue contribution to peak sales in excess of $1 billion.

Reasons to Buy This Report

With filing expected to occur in the US within the next few months, this week's Physician Views poll targets general practitioners and internal medicine specialists based in the US to gauge their current perception to use of a GLP-1 agonist for the treatment of obesity.

• How would you describe the impact of new obesity treatments (Qsymia, Belviq) in terms of the overall efficacy of available therapies?
• Have you ever prescribed a GLP-1 agonist (i.e. Victoza) in an off-label capacity for the treatment of obesity?
• If approved for the treatment of obesity (and based on available Phase III data), in what percentage of obese patients would you consider prescribing Victoza?
• If approved for the treatment of obesity (and based on available Phase III clinical data), in what percentage of pre-diabetic obese patients would you consider prescribing Victoza?
• What factors would act to limit your use of liraglutide for the broader treatment of obesity (i.e. among both pre-diabetes and non pre-diabetes patients)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Human Microbiome Market by Indication, Application, Product, Product Research, Technology Research - Global Forecast to 2025

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The global human microbiome market is estimated to reach USD 899.1 million by 2025, growing at a CAGR of 21.1% during the forecast period (2022–2025) Factors such as increased focus on human microbiome ...

Opportunity in Obesity Therapeutics in global market - 2017

  • $ 4500
  • Industry report
  • March 2017
  • by Feedback Business Consulting

This report provides insight into the current market scenario, structure and practices. In depth market scenario includes: - Current market size estimate - Revenues by players - Top 5 Companies - Market ...

Global Anti-Obesity Drugs Market - Growth, Trends & Forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The Global market for Anti-Obesity drugs Market is expected to reach $XX by the end of 2020 growing at a CAGR of around XX% from 2015 to 2021. Obesity generally refers to a condition where a person is ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.